The importance of cognitive testing
Cognition covers the mental processes involved in acquiring, processing, and using information. Because these processes underpin so many aspects of health, from psychiatric wellbeing to neurodegeneration, cognitive testing has become a widely used tool in research across a broad range of study types.
Neuropsychiatric versus neurodegenerative conditions
These two categories are often conflated but are distinct.
Neuropsychiatric conditions (anxiety, depression, stress, schizophrenia, OCD, mania) involve changes in neurophysiology and neurotransmitter function that affect mood, emotion, and behaviour. They are not primarily caused by cell death or structural degeneration.
Neurodegenerative conditions (Alzheimer's disease, Parkinson's disease) involve the actual decline or loss of nerve cells. They typically have genetic, age-related, and inflammatory components, and often produce visible pathology: amyloid-beta accumulation in Alzheimer's tissue, for example.
The distinction matters for research design because these conditions respond to different interventions and require different measurement approaches.
Why cognitive testing matters now
Depression, stress, and anxiety have increased significantly over the past decade. Metabolic conditions including obesity, diabetes, and autoimmune disorders have also grown in prevalence, and research now links psychiatric and metabolic conditions as risk factors for neurodegenerative disease. The Alzheimer's Society estimates over 850,000 people are living with dementia in the UK, with global figures approaching 50 million.
Cognitive monitoring across populations, whether in clinical settings or among otherwise healthy participants, provides data that can inform both prevention and treatment research. The question that follows naturally, especially for a study team weighing up remote or decentralised designs, is whether cognitive tests hold up when moved out of a supervised clinic room and onto a participant's own device.
Which tests to use and when
Executive function tests. The Stroop Test, Wisconsin Card Sorting Test, and Trail Making Test assess working memory, attention, and response control. They are useful across conditions including epilepsy, depression, traumatic brain injury, and neurodegeneration.
Attention and processing speed tests. Match-To-Sample (MTS) and Rapid Serial Visual Processing (RSVP) tests measure how accurately and quickly participants identify patterns within stimulus streams. These are particularly sensitive for depression, autism, epilepsy, and neurodegenerative conditions.
Memory tests. The Digit Span test asks participants to repeat increasingly long number sequences, providing a reproducible measure of working memory capacity. Delayed Match-To-Sample variants extend the test by introducing a time gap between stimulus and recall.
Mental status tests. The Mini-Mental State Examination (MMSE) is the most widely used assessment of cognitive decline, covering recall, language, and attention in a 30-point format. The Montreal Cognitive Assessment (MoCA) and Addenbrooke's Cognitive Examination (ACE-R) serve similar purposes and are sensitive to different severity levels.
Self-report psychiatric scales. The GAD-7 (General Anxiety Disorder), PANAS (Positive and Negative Affect Schedule), and SPANE (Scale of Positive and Negative Experience) capture subjective wellbeing and mood. These are non-interactive but provide important context alongside objective performance measures.
Does remote, self-administered testing actually hold up?
This isn't a hypothetical concern. A study examining a web-based remote cognitive screening platform followed 1,950 invited participants aged 35 to 100, most cognitively unimpaired but 9.3% with diagnosed cognitive impairment. The results were reassuring on one measure and more cautious on another. Among those who started a session, completion rates were 98.5%, and remained above 97% even in participants aged 80 and over. Adherence held up at follow-up too, with 89% of participants still completing sessions 7.5 months later, at an average session length of just 16 minutes.
The more cautious finding was in who chose to take part in the first place, not who finished once they'd started. Participation rates were meaningfully lower among cognitively impaired participants (33.1%) than cognitively unimpaired ones (65.4%), and lower among those with fewer years of education. In other words, once someone begins a remote cognitive test, they're highly likely to complete it, regardless of age or cognitive status. Getting people to begin in the first place is the part that still varies systematically by exactly the population characteristics a study most needs to capture representatively.
Combining tests in practice
No single test covers everything. A well-designed cognitive battery combines tests across these categories to build a comprehensive picture of a participant's cognitive profile. Quality of life and wellbeing measures are increasingly included alongside performance-based assessments, recognising that the two do not always move in parallel and that both matter to participants.
For studies considering a remote or hybrid design, the evidence above suggests the technology itself is rarely the limiting factor. The bigger design question is how to make initial participation genuinely accessible to people with lower digital confidence, less formal education, or existing cognitive impairment, since those are precisely the groups a cognitive health study is often trying hardest to reach. A platform that performs beautifully once someone opens it is only half the job if the invitation and onboarding process quietly filters out the participants the research most needs.